Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis

OBJECTIVE: Recently, several researchers have reported the incidence of cardiac-related toxicities occurring with nivolumab (Opdivo) and pembrolizumab (Keytruda). There is still a need for balance between oncology treatment efficacy and reduction of cardiotoxicity burden in immune checkpoint inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndjana Lessomo, Fabrice Yves, Wang, Zhiquan, Mukuka, Chishimba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090546/
https://www.ncbi.nlm.nih.gov/pubmed/37064101
http://dx.doi.org/10.3389/fonc.2023.1080998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090546/
https://www.ncbi.nlm.nih.gov/pubmed/37064101
http://dx.doi.org/10.3389/fonc.2023.1080998

Ejemplares similares